Oral composition containing sodium chloride

Abstract

[Problem] To provide an oral composition that contains high concentrations of fluorine, β-glycyrrhetinic acid, and sodium chloride while achieving stabilization of the β-glycyrrhetinic acid. [Solution] An oral composition containing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content is 1,000 ppm or more, and the pH is 5.3-7.5.

Description

Oral composition containing sodium chloride

[0001] The present disclosure relates to an oral composition that contains β-glycyrrhetinic acid and a high concentration of fluorine, while allowing β-glycyrrhetinic acid to exist stably.

[0002] Conventionally, β-glycyrrhetinic acid has been widely known as a component that provides effects including an anti-inflammatory effect, an alveolar bone resorption inhibitory effect for periodontal disease, and a histamine release inhibitory effect, and has been used in oral compositions. However, since β-glycyrrhetinic acid becomes unstable during long-term storage, it is known to incorporate sodium chloride into oral compositions for the purpose of improving its storage stability (Patent Document 1).

[0003] In addition, for the prevention of dental caries, the use of a dentifrice containing a fluorine compound is recommended as a daily self-care practice. Fluorine compounds impart resistance to acid produced by cariogenic bacteria to teeth, repair initial caries through remineralization, and restore teeth to their original healthy state, and are widely used in oral compositions. Furthermore, fluorine compounds also have an effect of inhibiting the proliferation of cariogenic bacteria (Patent Document 2).

[0004] JP-A-63-035515, JP-A-2021-107362

[0005] The present inventor has studied the storage stability of β-glycyrrhetinic acid in the formulation of an oral composition containing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride. The present inventor found that when fluorine is contained in the oral composition at a general concentration, β-glycyrrhetinic acid can be stably stored in the oral composition, but faced the problem that when fluorine is contained at a high concentration, β-glycyrrhetinic acid in the oral composition becomes unstable. Destabilization of β-glycyrrhetinic acid reduces the anti-inflammatory effect of the oral composition, and is therefore an important problem that must be solved.

[0006] Accordingly, an object of the present disclosure is to provide an oral composition that contains high-concentration fluorine, β-glycyrrhetinic acid, and sodium chloride, while achieving stabilization of β-glycyrrhetinic acid.

[0007] To achieve the above objective, an oral composition is provided comprising a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content is 1000 ppm or more and the pH is 5.3 to 7.5.

[0008] According to this disclosure, it is possible to provide an oral composition that contains a high concentration of fluoride, β-glycyrrhetinic acid, and sodium chloride, while achieving stabilization of β-glycyrrhetinic acid. The oral composition can exhibit an anti-inflammatory effect due to β-glycyrrhetinic acid and a caries-preventive effect due to the high concentration of fluoride, and by adjusting the pH of the oral composition to the range of 5.3 to 7.5, the problem of β-glycyrrhetinic acid destabilization caused by the high concentration of fluoride is solved. Furthermore, the oral composition of this disclosure with a pH adjusted to the range of 5.3 to 7.5 exhibits a taste-correcting effect on the oral composition and an improvement in the smoothness of the tooth surface compared to an oral composition with a pH of less than 5.3.

[0009] 1. Oral Composition of the Disclosure The Disclosure provides an oral composition comprising a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content is 1000 ppm or more and the pH is 5.3 to 7.5 (the oral composition of the Disclosure).

[0010] (Fluorine compounds) The oral compositions of this disclosure contain fluorine compounds.

[0011] In the oral composition disclosed herein, the fluoride compound is a known component that imparts resistance to acids produced by cariogenic bacteria to teeth, has the effect of remineralizing early caries, and also has the effect of suppressing the growth of cariogenic bacteria.

[0012] The fluorine compounds used in the oral compositions of this disclosure are not particularly limited as long as they are applicable in the oral cavity, but examples include alkali metal fluorides, fluorophosphates, fluorophosphates, stannous fluoride, and silver diamine fluoride. The fluorine compounds may be used alone or in combination of two or more. From the viewpoint of obtaining the above-mentioned effects on dental caries, at least one selected from the group consisting of alkali metal fluorides, fluorophosphates, and fluorophosphates is preferred as the fluorine compound, and fluorophosphates are preferred.

[0013] The alkali metal fluoride is not particularly limited as long as it is applicable in the oral cavity, but examples include sodium fluoride and potassium fluoride. The alkali metal fluoride may be used alone or in combination of two or more types. Among the alkali metal fluorides exemplified above, sodium fluoride is preferred from the viewpoint of obtaining the above-mentioned effect on dental caries significantly.

[0014] The fluorophosphate is not particularly limited as long as it can be applied in the oral cavity, but examples include monofluorophosphate and difluorophosphate. The fluorophosphate may be used alone or in combination of two or more types. Among the fluorophosphates exemplified above, monofluorophosphate is preferred from the viewpoint of obtaining the above-mentioned effects on dental caries.

[0015] The fluorophosphate is not particularly limited as long as it is applicable in the oral cavity, but examples include alkali metal salts of fluorophosphate, specifically sodium salts and potassium salts of fluorophosphate. The fluorophosphate may be used alone or in combination of two or more types. Among the fluorophosphates exemplified above, sodium salts are preferred, and sodium monofluorophosphate is more preferred, from the viewpoint of obtaining the above-mentioned effects on dental caries.

[0016] In the oral composition of this disclosure, the fluorine content in the oral composition is 1000 ppm or more in order to impart the above-mentioned effect against dental caries. Although the oral composition of this disclosure contains a high concentration of fluorine of 1000 ppm or more, as described later, the pH of the oral composition of this disclosure is adjusted to 5.3 to 7.5, so that the destabilization of β-glycyrrhetinic acid caused by the high concentration of fluorine is suppressed.

[0017] In the oral composition of this disclosure, the lower limit of the fluorine content in the oral composition is 1000 ppm or more, preferably 1100 ppm or more, more preferably 1200 ppm or more, even more preferably 1300 ppm or more, and even more preferably 1400 ppm or more, from the viewpoint of imparting the above-mentioned effects against dental caries. As described later, the oral composition of this disclosure has a pH adjusted to 5.3 to 7.5, so even if the oral composition of this disclosure contains 1000 ppm or more of fluorine, the destabilization of β-glycyrrhetinic acid can be suppressed. Furthermore, in the oral composition of this disclosure, there is no particular upper limit to the fluorine content in the oral composition, but for example, it is 1500 ppm or less.

[0018] In one embodiment of the oral composition of the present disclosure, when the fluorine compound is sodium monofluorophosphate, the content of sodium monofluorophosphate is, for example, 0.76 to 1.14% by weight, preferably 0.83 to 1.14% by weight, more preferably 0.91 to 1.14% by weight, even more preferably 0.99 to 1.14% by weight, and most preferably 1.06 to 1.14% by weight, from the viewpoint of imparting the above-mentioned effect against dental caries to the oral composition.

[0019] (β-Glycyrrhetinic acid) The oral composition of this disclosure contains β-glycyrrhetinic acid.

[0020] In the oral compositions disclosed herein, β-glycyrrhetinic acid is a known component incorporated into oral compositions as an ingredient that provides anti-inflammatory effects, inhibits alveolar bone resorption due to periodontal disease, and inhibits histamine release. β-glycyrrhetinic acid may be derived from natural sources or chemically synthesized. When derived from natural sources, it can be obtained by hydrolysis of glycyrrhizic acid obtained from licorice.

[0021] In the oral composition of this disclosure, the content of β-glycyrrhetinic acid is appropriately set according to the formulation form and use of the oral composition, but is, for example, 0.10 to 1.50 parts by weight per 1 part by weight of fluorine. Furthermore, from the viewpoint of exhibiting excellent anti-inflammatory effects and stabilizing the β-glycyrrhetinic acid contained in the oral composition, the content of β-glycyrrhetinic acid is, for example, 0.67 to 1.00 parts by weight, preferably 0.67 to 0.91 parts by weight, more preferably 0.67 to 0.83 parts by weight, even more preferably 0.67 to 0.77 parts by weight, and most preferably 0.67 to 0.71 parts by weight per 1 part by weight of fluorine.

[0022] In one embodiment of the oral composition of the present disclosure, when the fluorine compound is sodium monofluorophosphate, the content of β-glycyrrhetinic acid is, for example, 0.01 to 0.15 parts by weight per 1 part by weight of sodium monofluorophosphate. Furthermore, from the viewpoint of exhibiting excellent anti-inflammatory effects and stabilizing the β-glycyrrhetinic acid contained in the oral composition, the content of β-glycyrrhetinic acid is, for example, 0.088 to 0.132 parts by weight, preferably 0.088 to 0.120 parts by weight, more preferably 0.088 to 0.110 parts by weight, even more preferably 0.088 to 0.102 parts by weight, and most preferably 0.088 to 0.094 parts by weight per 1 part by weight of sodium monofluorophosphate.

[0023] In the oral compositions of this disclosure, the content of β-glycyrrhetinic acid is appropriately set according to the formulation form and use of the oral composition, but for example, it is 0.005 to 1% by weight. Furthermore, from the viewpoint of exhibiting excellent anti-inflammatory effects and stabilizing the β-glycyrrhetinic acid contained in the oral composition, the content of β-glycyrrhetinic acid is, for example, 0.01 to 0.5% by weight, preferably 0.02 to 0.3% by weight, more preferably 0.03 to 0.2% by weight, and even more preferably 0.04 to 0.1% by weight.

[0024] (Sodium Chloride) The oral compositions of this disclosure contain sodium chloride.

[0025] In the oral composition of this disclosure, sodium chloride is incorporated into the oral composition to suppress the destabilization of β-glycyrrhetinic acid caused by high concentrations of fluoride.

[0026] In the oral composition of this disclosure, the sodium chloride content is, for example, 0.05 to 0.5 parts by weight per 1 part by weight of β-glycyrrhetinic acid, from the viewpoint of suppressing the destabilization of β-glycyrrhetinic acid caused by high concentrations of fluorine.

[0027] In the oral composition of this disclosure, the sodium chloride content is appropriately set according to the formulation form and use of the oral composition, but for example, it is 0.005 to 0.02% by weight.

[0028] (pH) The oral compositions of this disclosure have a pH of 5.3 to 7.5.

[0029] In the oral composition of this disclosure, the pH is adjusted to a range of 5.3 to 7.5 from the viewpoint of stabilizing the β-glycyrrhetinic acid contained in the oral composition. If the pH of the oral composition is less than 5.3, the destabilization of β-glycyrrhetinic acid caused by high concentrations of fluorine cannot be suppressed, and the problems of this disclosure cannot be solved.

[0030] In the oral composition of this disclosure, the pH of the oral composition is a value measured at a temperature of 25°C. To adjust the pH to a range of 5.3 to 7.5, buffering agents, pH adjusters, etc., may be used.

[0031] In the oral compositions disclosed herein, the pH can be adjusted to a range of 5.3 to 7.5 by known means, and can be carried out according to the glass electrode method. In this specification, pH is a value measured in accordance with the method of measuring the pH value of an aqueous solution at 25°C using a pH meter with a glass electrode as specified in JIS K 2269 (Method of pH Measurement).

[0032] (Dosage Form, Form of Use) In the oral compositions of this disclosure, the dosage form or form of use is not particularly limited as long as it can be applied to the oral cavity, but examples include liquid or semi-solid forms (e.g., gel, paste, etc.).

[0033] The dosage form or form of use of the oral composition of this disclosure is not particularly limited as long as it can be applied to the oral cavity and remain there for a certain period of time. Examples include oral hygiene agents such as liquid toothpaste, tooth paste, mouthwash (mouthwash is sometimes referred to as mouth rinse, mouthwash, dental rinse, etc.), oral fresheners (such as mouth spray), and oral ointment. Preferably, liquid toothpaste, tooth paste, and mouthwash are included.

[0034] The method for preserving the oral composition of this disclosure is not particularly limited as long as sodium chloride suppresses the destabilization of β-glycyrrhetinic acid by high concentrations of fluorine. For example, the storage temperature can be 0 to 45°C, preferably 0 to 30°C, and more preferably 0 to 15°C.

[0035] In addition to the components described above, the oral composition of the present disclosure may contain components commonly used in the art according to the form of the oral composition, within a range that does not impair the effects of the pharmaceutical composition of the present disclosure, the anti-inflammatory effect of β-glycyrrhetinic acid, the caries prevention effect of a fluorine compound, the destabilization inhibitory effect of sodium chloride on β-glycyrrhetinic acid, and the destabilization inhibitory effect of β-glycyrrhetinic acid achieved by adjusting the oral composition of the present disclosure to a pH within the range of 5.3 to 7.5. Examples of components commonly used in the art include anti-inflammatory agents, antibacterial agents, hemostatic agents, hypersensitivity inhibitors, stabilizers, humectants, solubilizers, thickeners, abrasives, whitening agents, astringents, corrigents, detergents, pH adjusters, foaming agents, coloring agents, preservatives, bases, cleaning agents, and the like.

[0036] Examples of the anti-inflammatory agent include dipotassium glycyrrhizinate and the like.

[0037] Examples of the antibacterial agent include cetylpyridinium chloride and the like.

[0038] Examples of the hemostatic agent include ε-aminocaproic acid and the like.

[0039] Examples of the hypersensitivity inhibitor include aluminum lactate and the like.

[0040] Examples of the stabilizer include DL-alanine, disodium edetate, titanium dioxide, metaphosphate and the like.

[0041] Examples of the humectant include concentrated glycerin, PG, sorbitol solution and the like.

[0042] Examples of the solubilizer include ethanol, polyoxyethylene hydrogenated castor oil and the like.

[0043] Examples of the thickener include carrageenan, silicic anhydride, sodium carboxymethylcellulose and the like.

[0044] Examples of the abrasive include hydrated silicic acid, calcium pyrophosphate and the like.

[0045] Examples of the whitening agent include titanium dioxide and the like.

[0046] Examples of astringents include Angelica acutiloba root extract (1), Paeonia lactiflora root extract, and the like.

[0047] Examples of flavor-masking agents include sodium chloride, sodium saccharin, and the like.

[0048] Examples of detergents include Sapindus mukurossi fruit extract and the like.

[0049] Examples of pH adjusters include sodium hydroxide and the like.

[0050] Examples of foaming agents include sodium N-lauroyl-L-glutamate, sodium lauryl sulfate, alkyl glycosides and the like.

[0051] Examples of colorants include Yellow No. 203, Blue No. 1 and the like.

[0052] Examples of preservatives include ethyl parahydroxybenzoate, propyl parahydroxybenzoate, parabens, and the like.

[0053] Examples of bases include purified water, sorbitol solution, and the like.

[0054] Examples of cleaning agents include propyldimethyl octadecyl ammonium chloride-bonded silicic anhydride (Bionium) and the like.

[0055] (Improvement of tooth surface smoothness) The oral composition of the present disclosure can be used for improving tooth surface smoothness.

[0056] The oral composition of the present disclosure can be used as an agent for improving tooth surface smoothness because, when applied in the oral cavity, it can effectively kill bacteria that form biofilms on tooth surfaces. The above-described effect is superior in the oral composition of the present disclosure having a pH of 5.3 or higher, as compared with an oral composition having a pH of less than 5.3.

[0057] The application amount of the oral composition of the present disclosure into the oral cavity is appropriately set according to the content of the active ingredient, the type of the active ingredient, the formulation form of the oral composition, expected effects, and the like. For example, the application amount may be set such that the application amount of the active ingredient per application corresponds to about 1 to 10 mg, at a frequency of 1 to 6 times per day.

[0058] 2. Method for producing the oral composition of the present disclosure (or method for stabilizing β-glycyrrhetinic acid of the present disclosure) The present disclosure provides a method for producing an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content of the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.5 (method for producing the oral composition of the present disclosure). The present disclosure also provides a method for stabilizing β-glycyrrhetinic acid in an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content of the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.5 (method for stabilizing β-glycyrrhetinic acid of the present disclosure).

[0059] In the method for producing the oral composition of this disclosure (or the method for stabilizing β-glycyrrhetinic acid of this disclosure), the fluorine compound, β-glycyrrhetinic acid, and sodium chloride may be the same as those described in the oral composition of this disclosure.

[0060] A method for producing the oral composition of the present disclosure (or a method for stabilizing β-glycyrrhetinic acid of the present disclosure) comprises the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride. The fluorine compound, β-glycyrrhetinic acid, and sodium chloride may be mixed simultaneously, or (i) the fluorine compound and β-glycyrrhetinic acid, (ii) the fluorine compound and sodium chloride, or (iii) β-glycyrrhetinic acid and sodium chloride may be mixed beforehand, and the remaining components may be mixed afterward.

[0061] Next, examples of the present disclosure will be described. However, the present disclosure is not limited to the following examples. Commercial reagents were used according to their respective protocols unless otherwise specified.

[0062] 1. Stability evaluation test of β-glycyrrhetinic acid. Samples with the compositions shown in Table 1 or 2 (Reference Example 1 or 2, Comparative Example 1 or 2, Examples 1 to 5) were prepared. Specifically, each component was mixed to prepare each paste-type toothpaste. Approximately 40 g of each toothpaste was filled into an aluminum laminate tube and stored at 40°C for 6 months. For each toothpaste, the residual amount of β-glycyrrhetinic acid was measured by high-performance liquid chromatography under the following conditions.

[0063]

[0064]

[0065] <Test Conditions> Equipment used: High-performance liquid chromatograph LC-20AD (Shimadzu Corporation) Detector: UV absorbance spectrophotometer - measurement wavelength 350 nm Column: ODS column, length 15 cm Column temperature: 40°C Mobile phase: EDTA + phosphate buffer / acetonitrile mixture Flow rate: 1.0 mL / min

[0066] Test Example 1 The stability of β-glycyrrhetinic acid after storage of Reference Examples 1 and 2, Comparative Example 1, and Examples 1 to 4 prepared above was tested under the above conditions. When stored for 6 months at 40°C, Reference Example 2 (pH 5.1), which contained low concentrations of fluorine and sodium chloride, had a residual amount of β-glycyrrhetinic acid of 95% or more, indicating no problems. However, Comparative Example 1 (pH 5.1), which contained high concentrations of fluorine and sodium chloride, had a residual amount of β-glycyrrhetinic acid of less than 95%, indicating instability. On the other hand, in Examples 1 (pH 5.3), 2 (pH 5.5), 3 (pH 6.0), and 4 (pH 7.5), which contained high concentrations of fluorine and sodium chloride, the residual amount of β-glycyrrhetinic acid recovered to 95% or more, maintaining stability. The results are shown in Table 3.

[0067]

[0068] ​Test Example 2 The stability of β-glycyrrhetinic acid after storage of Comparative Example 2 and Example 5 prepared above was tested under the above conditions. When stored for 6 months at 40°C, Comparative Example 2 (pH 5.1), which contained high concentrations of fluorine and sodium chloride, showed that the remaining amount of β-glycyrrhetinic acid was less than 95% (94.4%), indicating instability. On the other hand, in Example 2 (pH 5.5), which contained high concentrations of fluorine and sodium chloride, the remaining amount of β-glycyrrhetinic acid recovered to 95% or more (97.5%), maintaining stability. The results are shown in Table 4.

[0069]

[0070] 3. Monitor Test (1) Purpose of the Study The purpose of this study was to verify the user experience of Comparative Example 3 and Example 5 using a physician-initiated blinding method, targeting users of Kobayashi Pharmaceutical's commercially available toothpaste (product name: Seiyo d).

[0071] (2) Overview of the survey Approximately 80 men and women who regularly use Kobayashi Pharmaceutical's commercially available toothpaste (product name: Seiyo d) and meet the requirements for survey participants were surveyed on their experience using Comparative Example 3 and Example 5 when brushing their teeth.

[0072] (3) Survey Design: Survey participants were given an explanation of the survey content using explanatory materials, and the survey was conducted only for those participants who agreed to the survey content.

[0073] (4) Samples and amounts used (a) Samples were prepared with the compositions shown in Table 5 (Example 5, Comparative Example 3). Specifically, each component was mixed to prepare each paste-type toothpaste.

[0074]

[0075] (i) Sample packaging: Each sample was filled into an aluminum laminate tube (100g capacity). (iii) Handling and storage of the sample: After filling the tube, it was stored at room temperature. (iv) Amount of sample to use: Take an appropriate amount onto a toothbrush and brush your teeth and gums. (5) Requirements for Survey Participants (a) Selection Criteria for Survey Participants (those who meet the conditions of (i) and (ii)) (i) Healthy men and women aged 20 or older (ii) Healthy men and women who regularly use Kobayashi Pharmaceutical's commercially available toothpaste (product name: Seiyo d) (b) Exclusion Criteria for Survey Participants (those who meet any of the conditions of (i) to (xi)) (i) Those who do not intend to use the sample at least once a day (ii) Those with drug sensitivities such as allergies (iii) Those who have one of the five major diseases (cancer, stroke, acute myocardial infarction, diabetes, mental illness), etc., and are receiving treatment at a medical institution or are scheduled to undergo surgery, etc. (iv) Pregnant women, those who may be pregnant, or breastfeeding women (v) Those who have taken antibiotics within the last month (vi) Those who have had a tooth extracted or undergone periodontal surgery, etc. within the last year (vii) Those who are currently receiving treatment for oral problems at a dental clinic (viii) Those who wear complete dentures (ix) Those with obvious injuries in the oral cavity (x) Individuals with severe gingivitis (xi) Others whom the research physician or principal investigator deems unsuitable as research participants

[0076] (5) Research Method (a) Research Flow A research company contacted individuals who had experience using Kobayashi Pharmaceutical's commercially available toothpaste (product name: Seiyo d) to gather research participants who met the above requirements and were able to participate in the study, and obtained their consent to participate in the study. The research participants were divided into two groups (Study A and Study B) and evaluated their user experience for four weeks as follows: (Study A) Comparative Example 3 was used for two weeks and the user experience was evaluated, followed by the use of Example 5 for two weeks and the user experience was evaluated. (Study B) Example 5 was used for two weeks and the user experience was evaluated, followed by the use of Comparative Example 3 for two weeks and the user experience was evaluated.

[0077] (6) Results Example 5 and Comparative Example 3 were evaluated for bitterness, taste, and the feeling of smoothness of the teeth after brushing or remaining in the mouth after brushing (Tables 6-9). As a result, Comparative Example 3 (pH 5.5), which contained β-glycyrrhetinic acid, high concentration of fluoride and sodium chloride, showed improvement in all of the above evaluation items compared to Comparative Example 3 (pH 5.1), which contained β-glycyrrhetinic acid, high concentration of fluoride and sodium chloride.

[0078]

[0079]

[0080]

[0081]

[0082] Although the present disclosure has been described above with reference to embodiments, the present disclosure is not limited to the embodiments described above. Various modifications to the structure and details of the present disclosure may be made that will be understood by those skilled in the art within the scope of the present disclosure.

[0083] The patents, patent applications, and documents cited herein are incorporated herein by reference in the same manner as their contents are specifically described herein.

[0084] <Notes> Some or all of the above embodiments and examples may be described as follows, but are not limited to the following. <Oral Compositions of the Disclosure> (Note 1) An oral composition comprising a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content is 1000 ppm or more and the pH is 5.3 to 7.5. (Note 2) The oral composition according to Note 1, wherein the fluorine compound is at least one selected from the group consisting of alkali metal fluorides, fluorophosphate, and salts of fluorophosphate. (Note 3) The oral composition according to Note 1 or 2, wherein the fluorine compound is sodium monofluorophosphate. (Note 4) The oral composition according to any one of Notes 1 to 3, wherein the fluorine content is 1500 ppm or less. (Note 5) The oral composition according to any one of Notes 1 to 4, which is a liquid toothpaste, a paste toothpaste, or a mouthwash. (Note 6) An oral composition according to any one of Notes 1 to 5, used for improving the smoothness of tooth surfaces. <Method for producing the oral composition of the present disclosure> (Note 7) A method for producing an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content in the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.5. <Method for stabilizing β-glycyrrhetinic acid of the present disclosure> (Note 8) A method for stabilizing β-glycyrrhetinic acid in an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content in the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.5.

[0085] According to this disclosure, it is possible to provide an oral composition that contains a high concentration of fluoride, β-glycyrrhetinic acid, and sodium chloride, while achieving stabilization of β-glycyrrhetinic acid. The oral composition can exhibit an anti-inflammatory effect due to β-glycyrrhetinic acid and a caries-preventive effect due to a higher concentration of fluoride than conventional compositions, and by adjusting the pH of the oral composition to the range of 5.3 to 7.5, the problem of β-glycyrrhetinic acid destabilization caused by the high concentration of fluoride is solved. Furthermore, the oral composition of this disclosure with a pH adjusted to the range of 5.3 to 7.5 exhibits a taste-correcting effect on the oral composition and an improvement in the smoothness of the tooth surface compared to an oral composition with a pH of less than 5.3.

Claims

1. An oral composition comprising a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content is 1000 ppm or more and the pH is 5.3 to 7.

5.

2. The oral composition according to claim 1, wherein the fluorine compound is at least one selected from the group consisting of alkali metal fluorides, fluorophosphates, and salts of fluorophosphates.

3. The oral composition according to claim 1 or 2, wherein the fluorine compound is sodium monofluorophosphate.

4. The oral composition according to any one of claims 1 to 3, wherein the fluorine content is 1500 ppm or less.

5. An oral composition according to any one of claims 1 to 4, which is a liquid toothpaste, a paste toothpaste, or a mouthwash.

6. An oral composition according to any one of claims 1 to 5, used for improving the smoothness of a tooth surface.

7. A method for producing an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content in the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.

5.

8. A method for stabilizing β-glycyrrhetinic acid in an oral composition, comprising the step of mixing a fluorine compound, β-glycyrrhetinic acid, and sodium chloride, wherein the fluorine content in the oral composition is 1000 ppm or more, and the pH of the oral composition is 5.3 to 7.5.

Images